Yea so true… sellers fading though, hopefully next week we go over$6

Thank you for schooLing him again ;)

Easy now… it is time, i just bought in… if you ate in you Win. Bios is the play!

Double my position… no worries this will BOOM! MM’s playing and will let this ride soon.

It’s going!……!

Agree, well said bio!

Hope to see a Forward split filing very soon!

Where can i buy this? On Ameritrade the BUY cost is way up $0.07

Awesome, exciting days ahead!

Oh wow 2?!!! Dang so fortunate to buy in few days ago for the very 1st time @ $1.68. I more funds clearing Wednesday to add. Thank you for all your DD on this board.

Let’s go! ALL CLEAR - Pathway to success on hand, looking forward to the forward split.

Thank you!

What is the record date to qualify for the upcoming forward split 5:1 ???

Not sure how the process work, are people buying today qualify?

Let’s GO!!! - Per GS tweet: Steve Magami's attorney has just informed $SRNW's attorney that they won't be pursuing the matter any further.

This company GRFXY is still so under the radar. It just up-listed last Friday 8/12/22 on the NYSE and will change to GRFX by Tuesday i believe. $NIO, $TSLA, $VWAGY are all scrambling for it. $GRFXY is set to be big in this space??
https://finance.yahoo.com/news/why-tesla-volkswagen-nio-scrambling-233000536.html

Thank you, and yes there is still 9.7 million C’s left.

Good point

HUGE Buys @ 0.0013

What’s the ask right know?

Old news, that was approved…

MASSIVE! The market for this patent are in the billions.

**BOOM!!!**

Are pro RGBP now?

BIG Fat buy 930k @ .0097

Whoa! .0077 big buys

Our CEO David will deliver, count on iT!

I would like to see partnerships with big pharma! President and soon to be CEO Cyrus Arman is cooking something up! Imo

Maybe they’ll partner w/ us… $REGEN & $MRK

Exactly right

C’mon!!!! $4 more and i’ll be even… Let’s GO!

YES SIR! MOASS coming….!

LoL, exactly.

Can someone post this article?

Would a possible spin-off be part of this?

Why Seagen, should be NWBO, will see if that goes through.

“The INSPIRE study achieved its primary objective of identifying patient populations that may benefit from IRX-2 in the neoadjuvant setting,” said Matt Angel, Ph.D., Brooklyn’s CEO. “These encouraging results are a testament to the design of the INSPIRE study and provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors. The potential to offer an effective, well tolerated treatment to patients with advanced head and neck cancer who are ineligible for chemotherapy is particularly exciting.”

Nice one! Hehehe…

Good post

Great stuff BB!

Ditto! Senti is a master of due diligence.